{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:41:52Z","timestamp":1790948512981,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Epigenetics of Haematopoiesis Laboratory is funded by grants from The Oglesby Charitable Trust."},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW109-TDU-B-211-134009"],"award-info":[{"award-number":["MOHW109-TDU-B-211-134009"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-002-221"],"award-info":[{"award-number":["MOST 109-2314-B-002-221"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-002-222"],"award-info":[{"award-number":["MOST 109-2314-B-002-222"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-002-280"],"award-info":[{"award-number":["MOST 111-2314-B-002-280"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01087-7","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T07:03:10Z","timestamp":1720767790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-5627","authenticated-orcid":false,"given":"Yu-Hung","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Gurashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-9445","authenticated-orcid":false,"given":"Chi-Yuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-698X","authenticated-orcid":false,"given":"Wen-Chien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-5593","authenticated-orcid":false,"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-0979","authenticated-orcid":false,"given":"Kiran","family":"Batta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-1402","authenticated-orcid":false,"given":"Daniel H.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"1087_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome Atlas. Cell Rep. 2019;28:1370\u201384.e5.","journal-title":"Cell Rep"},{"key":"1087_CR2","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347\u201354.","journal-title":"Blood"},{"key":"1087_CR3","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/bloodadvances.2021005859","volume":"6","author":"RR Schimmer","year":"2022","unstructured":"Schimmer RR, Kovtonyuk LV, Klemm N, Fullin J, Stolz SM, Mueller J, et al. TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood Adv. 2022;6:3201\u20136.","journal-title":"Blood Adv"},{"key":"1087_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/s41375-023-01964-3","volume":"37","author":"M Gurney","year":"2023","unstructured":"Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, et al. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia. 2023;37:1753\u20136.","journal-title":"Leukemia"},{"key":"1087_CR5","unstructured":"AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818-31."},{"key":"1087_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","volume":"20","author":"A Hafner","year":"2019","unstructured":"Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20:199\u2013210.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1087_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjh.18681","volume":"201","author":"Y-H Wang","year":"2023","unstructured":"Wang Y-H, Yao C-Y, Lin C-C, Gurashi K, Amaral FMR, Bossenbroek H, et al. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia. Br J Haematol. 2023;201:302\u20137.","journal-title":"Br J Haematol"},{"key":"1087_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/bjh.15408","volume":"182","author":"AM Hurtado","year":"2018","unstructured":"Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, et al. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. Br J Haematol. 2018;182:373\u201383.","journal-title":"Br J Haematol"},{"key":"1087_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","volume":"20","author":"A Unnikrishnan","year":"2017","unstructured":"Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, et al. Integrative genomics identifies the molecular basis of resistance to Azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20:572\u201385.","journal-title":"Cell Rep"},{"key":"1087_CR10","doi-asserted-by":"crossref","unstructured":"Shi D, Jiang P. A different facet of p53 Function: regulation of immunity and inflammation during tumor development. Front Cell Dev Biol. 2021;9:762651.","DOI":"10.3389\/fcell.2021.762651"},{"key":"1087_CR11","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142\u221265.","DOI":"10.1002\/ajh.27271"},{"key":"1087_CR12","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1182\/blood-2018-99-118780","volume":"132","author":"DA Sallman","year":"2018","unstructured":"Sallman DA, Borate U, Cull EH, Donnellan WB, Komrokji RS, Steidl UG, et al. Phase 1\/1b study of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, as monotherapy or in combination with cytarabine for the treatment of relapsed\/refractory AML and advanced MDS with TP53 Wild-Type. Blood. 2018;132:4066.","journal-title":"Blood"},{"key":"1087_CR13","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","volume":"55","author":"A Rodriguez-Meira","year":"2023","unstructured":"Rodriguez-Meira A, Norfo R, Wen S, Ch\u00e9deville AL, Rahman H, O\u2019Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55:1531\u201341.","journal-title":"Nat Genet"},{"key":"1087_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1182\/blood-2016-06-719237","volume":"129","author":"J Zhang","year":"2017","unstructured":"Zhang J, Kong G, Rajagopalan A, Lu L, Song J, Hussaini M, et al. p53\u2212\/\u2212 synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia. Blood. 2017;129:358\u201370.","journal-title":"Blood"},{"key":"1087_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.18632\/oncotarget.13483","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Sun Q. TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2017;8:624\u201343.","journal-title":"Oncotarget"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01087-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01087-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T07:06:43Z","timestamp":1720768003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01087-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1087"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01087-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Use of primary human tissue was in compliance with the ethical and legal framework of the UK\u2019s Human Tissue Act, 2004. Primary samples were from Manchester Cancer Research Centre\u2019s Tissue Biobank instituted with the approval of the South Manchester Research Ethics Committee (18\/NW\/0092) and licensed by the Human Tissue Authority (license number 30004). Use was authorized following ethical review by the Tissue Biobank\u2019s scientific sub-committee (approval 17_KIBA_01). The NTUH Research Ethics Committee approved the study (#201709072RINC). The study was approved by the institutional review boards of each participating hospital, with informed consent obtained in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"112"}}